A phase 3, multicenter, double-blinded, randomized, study to compare immunogenicity and safety between three commercial lots of StaphVAX, a bivalent Staphylococcus aureus glycoconjugate vaccine in normal, healthy, adult volunteers.

Trial Profile

A phase 3, multicenter, double-blinded, randomized, study to compare immunogenicity and safety between three commercial lots of StaphVAX, a bivalent Staphylococcus aureus glycoconjugate vaccine in normal, healthy, adult volunteers.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Staphylococcus aureus vaccine (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 11 May 2012 Actual end date Jul 2005 added as reported by ClinicalTrials.gov.
    • 03 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top